Investor Snapshot

Sienna identifies, develops and commercialises reagents and in vitro diagnostic tests that target an unmet need. Sienna has built a strong team and a global scientific, clinical, and commercial partner network.

Sienna's first product, for the detection of telomerase, has been validated through its adoption and use at major USA pathology laboratories. 

Current work programs are focussed on:

  • Market penetration of the telomerase technology platform in current IVD registered markets
  • Global market expansion for existing product
  • Scientific R&D both internal and through global partners to research expanded utility of telomerase product 
  • The search for additional biomarkers to feed the Sienna development and commercialisation engine    


Name Sienna Cancer Diagnostics Ltd. (ASX: SDX)
Business Description Sienna is a medical technology company that develops and commercialises in-vitro diagnostic products for the pathology market.
History Originally incorporated in Sydney, the Company is now headquartered on the outskirts of Melbourne in a business park alongside many other medical technology companies, both large and small. A public unlisted company until August 2017, Sienna started trading on the ASX as a public listed company on August 3rd, 2017.
Shares on issue Approximately 267 million
Share price at last capital raising $0.06 as part of Jul/Aug 2018 capital raise
Company structure  Public listed company 
Location  Head office and laboratory based at the Small Technologies Cluster, 1 Dalmore Drive, Scoresby, VIC 3179, Australia 
Auditor  Walker Wayland NSW
Chartered Accountants
8th Floor, 55 Hunter St
Sydney, NSW 2000 Australia Tel: +61-2- 9951-5400
Corporate Advisor

Matthew Lindh
Harbury Capital
+61 432 363 933

Company Secretary  Tony Di Pietro 
+61 (3) 8288 2141
Share Registry 

Link Market Services
Locked Bag A14
Sydney South, NSW 1235

Toll-free: 1300-554-474 (Australia only)
International: +61-1300-554-474

Sign up for updates